KEYNOTE-024 was a phase 3 study comparing pembrolizumab (200 mg Q3W) with platinum-containing chemotherapy in patients with treatment-naive advanced NSCLC with high PD-L1 expression (≥50%) [11]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.